




RealRate

PHARMACEUTICAL 2014

Sonoma Pharmaceuticals Inc
Rank 158 of 234



The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 36% points. The greatest weakness of Sonoma Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 138% points.

The company's Economic Capital Ratio, given in the ranking table, is 173%, being 70% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	11,534
Cost of Goods Sold	4,709
Intangible Assets	0
Liabilities, Current	5,127
Liabilities, Non-Current	676
Other Assets	231
Other Compr. Net Income	62
Other Expenses	1,232
Other Liabilities	2,681
Other Net Income	-825
Other Revenues	15,452
Property and Equipment	800
Research and Development	2,223
Selling, General and Administrative Expense	11,894

Output Variable	Value in 1000 USD
Assets	12,565
Liabilities	8,484
Expenses	20,058
Revenues	15,452
Stockholders Equity	4,081
Net Income	-5,431
Comprehensive Net Income	-5,400
BaseVar	28,723
ECR before Limited Liability	33%
Economic Capital Ratio	173%